Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise  SAN DIEGO, May  11, 2026  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on

ANAB

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

AnaptysBio Expands Leadership Team to Enhance Shareholder Value

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise  SAN DIEGO, May  11, 2026  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>AnaptysBio has strengthened its leadership by appointing Christopher Murphy as CFO and Owen Hughes to its Board. These strategic appointments aim to enhance business development and protect the company&#039;s royalty assets, signaling a commitment to maximizing shareholder value and efficiency in operations.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>AnaptysBio appoints Christopher Murphy as Chief Financial Officer.</li><li>Owen Hughes joins AnaptysBio&#039;s Board of Directors.</li><li>Both appointments aim to enhance business development and royalty management.</li><li>Leadership additions bolster the protection of royalty assets.</li><li>Focus on maximizing shareholder value remains a priority.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>GSK (GSK)</strong>: Collaboration on Jemperli may drive revenue for Anaptys.</li><li><strong>Vanda (VNDA)</strong>: Partnership for imsidolimab could benefit Anaptys&#039; financials.</li><li><strong>Third Harmonic Bio (THRD)</strong>: Murphy&#039;s experience here could attract investor interest.</li><li><strong>Horizon Therapeutics PLC (HZNP)</strong>: Acquisition by Amgen signifies potential for value generation.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as leadership changes can significantly influence a company’s strategic direction and overall performance, impacting investor sentiments and financial outcomes.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>New appointments may enhance investor confidence and boost share price.</li><li>Focus on increasing royalty revenue could drive future earnings.</li><li>Investors may react positively to strategic direction under new CFO.</li><li>The company could pursue more collaborations to enhance returns.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Christopher Murphy previously served as CFO of Third Harmonic Bio.</li><li>Owen Hughes has over two decades in royalty management.</li><li>AnaptysBio manages collaborations for Jemperli with GSK and imsidolimab with Vanda.</li><li>The company aims to return value from its royalty assets to shareholders.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider a bullish position on ANAB due to strengthened leadership focused on growth.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><ul><li>Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise</li></ul>  <p align="left">SAN DIEGO, May  11, 2026  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ANAB">ANAB</a>), a company focused on managing the financial collaborations for <em>Jemperli</em> with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.</p>  <p>"We are excited to welcome Chris, who will be fully dedicated to Anaptys, and Owen, both of whom deepen our team's strong mix of expertise across finance, business development, royalty management and strategic transactions," said Daniel Faga, president and chief executive officer. "We believe these strong additions will continue Anaptys' focus on protecting and returning the value of our royalty assets to shareholders."</p>  <p><strong>Christopher M. Murphy Appointed Chief Financial Officer</strong></p>  <p>Mr. Murphy has extensive experience in business development, corporate strategy and investment banking. He previously served as CFO and CBO of Third Harmonic Bio, where he was instrumental in maximizing shareholder value and returning value to shareholders. Prior to Third Harmonic, he served as a senior leader at Horizon Therapeutics PLC, where he played a key role in the company's transformation into a profitable rare‑disease business acquired by Amgen for $28 billion in 2023. His background includes leadership roles in both business development and commercial operations, as well as earlier experience in life sciences investment banking at JMP Securities.</p>  <p><strong>Owen Hughes Joins Board of Directors</strong></p>  <p>Mr. Hughes has more than two decades of leadership experience across royalty management, corporate development and investment management. He currently serves as CEO of XOMA Royalty, a biotech royalty company, and previously served as CEO of Sail Bio and CEO and co‑founder of Cullinan Oncology. His earlier roles include chief business officer and head, corporate development at Intarcia Therapeutics, following 16 years in investment roles at Brookside Capital and Pyramis Global Advisors. Hughes currently sits on the board of C4 Therapeutics, and was the former chairman or lead independent director of Ikena Oncology (IKNA), Radius Health and Translate Bio.</p>  <p>See their full bios <a href="https://www.globenewswire.com/Tracker?data=YOjuj1wwniExwIWsiuJC8_GHAcUCsmvYLfyRfQt6JG6akXzHOq83u9zg_FSjcRGx2jFFrYC3htXOX4AaA4MSm-wsGrHQ8jAhTrc9HZhCKOo=" rel="nofollow" target="_blank">here</a>.</p>  <p><strong>About Anaptys</strong></p>  <p>Anaptys manages the financial collaborations for <em>Jemperli</em> with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=M17fTFz2lpkCoUar8YbskQCWG09SbChQ7wKIX8LxQ42cVbO1dFLJKhkdjjyPJu6FqL6AJJSiFk3e5dcj4a88Nv7hpjEdVbYmwE18kKZ_4xQ=" rel="nofollow" target="_blank">www.AnaptysBio.com</a> or follow us on <a href="https://www.globenewswire.com/Tracker?data=Kg-BO644JB3_fslwmx-QD6UUzNwsKyHRbF1BXinqPfZd0bDkI3n82YFlUNTAEiF8YZllxZqu3fbNQx9LY7LG4Nm7GZQ2cX174y3ztQJBKoY=" rel="nofollow" target="_blank">LinkedIn</a>.<br></br><br></br><strong>Contact:</strong><br></br>Anaptys Investor Relations<br></br><a href="https://www.globenewswire.com/Tracker?data=_UcstLBEoca4A3aMSFcNG3nzJY1cYbT6atQZOu7xV_iF1mpKrGKa8lDNzHea8jn3Db5Pk5Moa01ySdQLiUZESRYNnbb-Wk4AU0Coii7ct4DkhkIZbvE6mdxB8HWJe5Cv" rel="nofollow" target="_blank">investors@anaptysbio.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxNzA0NCM3NTkyOTIwIzIwMjAxMjY="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZDA0YTc2ZmEtZDAxOS00YmQzLWIyYzQtMjJmNjk2OTMzMWMyLTEwMzE2OTgtMjAyNi0wNS0xMS1lbg==/tiny/AnaptysBio-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/eb223f66-e7e0-4e0a-94e7-a3f7a06b13ab"><img src="https://ml.globenewswire.com/media/eb223f66-e7e0-4e0a-94e7-a3f7a06b13ab/small/anaptys-logo-png.png" border="0" width="150" height="42" alt="Primary Logo"></img></a></p>

AnaptysBio has strengthened its leadership by appointing Christopher Murphy as CFO and Owen Hughes to its Board. These strategic appointments aim to enhance business development and protect the company's royalty assets, signaling a commitment to maximizing shareholder value and efficiency in operations.

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News